Cargando…

Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination

BACKGROUND: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has caused over 6 million deaths world-wide. In the pre-vaccination era, we noted a 5·3% SARS-CoV-2 IgG antibody positivity rate in 81,624 subjects. METHODS: Utilizing assays for serum SARS-CoV-2 spike (S) protein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dulipsingh, Latha, Lang, Maxine, Diffenderfer, Margaret R., Cook, Lisa, Puff, Jennifer, Diaz, Lynn, He, Lihong, Schaefer, Ernst J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759815/ https://www.ncbi.nlm.nih.gov/pubmed/36568023 http://dx.doi.org/10.1016/j.jcvp.2022.100130

Ejemplares similares

Corona Virus Disease-19 serology, inflammatory markers, hospitalizations, case finding, and aging
por: Schaefer, Ernst J., et al.
Publicado: (2021)

SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma
por: Dulipsingh, Latha, et al.
Publicado: (2020)

Comparing SARS-CoV-2 neutralizing antibody levels in convalescent unvaccinated, convalescent vaccinated, and naive vaccinated subjects
por: Dulipsingh, Latha, et al.
Publicado: (2023)

Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies
por: Vargas, Leonardo, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
por: Fonseca, Marcela Helena Gambim, et al.
Publicado: (2022)

Immunostimulating Effect of Inactivated Parapoxvirus Ovis on the Serological Response to Equine Influenza Booster Vaccination
por: Carnet, Flora, et al.
Publicado: (2022)

Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies
por: Huang, Chien-Tzu, et al.
Publicado: (2023)

Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
por: Ibrahim, Danyal, et al.
Publicado: (2020)

Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters
por: Burckhardt, Rachel M., et al.
Publicado: (2022)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
por: Lai, Kristi Tsz-Wan, et al.
Publicado: (2022)

Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination
por: Li, Jianhua, et al.
Publicado: (2022)

SARS-CoV-2 Breakthrough Infection after mRNA-1273 Booster among CoronaVac-Vaccinated Healthcare Workers
por: Santi, Theresia, et al.
Publicado: (2022)

IgA antibody dynamics in healthcare workers after CoronaVac® vaccination and heterologous Comirnaty® booster dose
por: Bochnia-Bueno, Lucas, et al.
Publicado: (2023)

Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster
por: da Silva, Almir Ribeiro, et al.
Publicado: (2022)

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
por: Atıcı, Serkan, et al.
Publicado: (2023)

Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant
por: Campos, Guilherme R. F., et al.
Publicado: (2022)

Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021
por: Ireland, Georgina, et al.
Publicado: (2022)

Booster Vaccination: The Role of Reduced Antigen Content Vaccines as a Preschool Booster
por: Gabutti, Giovanni, et al.
Publicado: (2014)

Serological Responses in Cattle following Booster Vaccination against Serotypes 4 and 8 Bluetongue Virus with Two Bivalent Commercial Inactivated Vaccines
por: Sailleau, Corinne, et al.
Publicado: (2022)

The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine
por: Farias, Jessica Pires, et al.
Publicado: (2022)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
por: Shmueli, Einat Shacham, et al.
Publicado: (2022)

SARS-CoV2 vaccine boosters for India
por: Kang, Gagandeep
Publicado: (2022)

SAT188 Atypical Parathyroid Adenoma: A Diagnostic Challenge Of Primary Hyperparathyroidism
por: Bendaram, Snigdha Reddy, et al.
Publicado: (2023)

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
por: Pérez-Then, Eddy, et al.
Publicado: (2022)

Corona and Reproduction, or Why the Corona Vaccination Does Not Result in Infertility
por: Braun, Anne-Sophie, et al.
Publicado: (2022)

Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination
por: Ramezani, Amitis, et al.
Publicado: (2014)

Antibody response dynamics to CoronaVac vaccine and booster immunization in adults and the elderly: A long-term, longitudinal prospective study
por: Volpe, Gustavo Jardim, et al.
Publicado: (2023)

Salivary, serological, and cellular immune response to the CoronaVac vaccine in health care workers with or without previous COVID-19
por: Ortega, Marina Mazzilli, et al.
Publicado: (2022)

Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era
por: Freund, Ophir, et al.
Publicado: (2022)

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
por: Assawasaksakul, Theerada, et al.
Publicado: (2021)

Serological makers of rubella infection in Africa in the pre vaccination era: a systematic review
por: Mirambo, Mariam M., et al.
Publicado: (2015)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Antibody response to SARS-CoV-2 booster vaccines
por: Loving, Hanna S., et al.
Publicado: (2022)

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
por: Wanchaijiraboon, Passakorn, et al.
Publicado: (2023)

Booster vaccinations protect shipboard personnel from COVID-19
por: Ryan, Margaret, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rtjf1t78t3jf1pdljt0nq6fc29